Procaps Group to Report First Quarter 2021 Financial Results on May 13, 2021 After the Market Close
Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.
- Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.
- Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model.
- Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.
- A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements.